$9.99
+0.08 (+0.81%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TTRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 2 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)NCT07355075Change in Investigator Global Assessment (IGA) at Week 8Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Combination product: GX-03 · Other: Vehicle | Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis | 110 | 2026-07-10 | 2026-05-18 |
| Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.NCT04951349Reduction of 60% in viral load from baselineRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: GX-03, Petrolatum ointment | Covid19 | 85 | 2021-05-30actual | 2021-07-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19